Table 3 Genotype distribution in relation to subsites in colorectal cancer
Genotype | Colon cancer | Rectal cancer | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
patients (n = 40) | controls (n = 121) | crude | adjusted | patients (n = 23) | controls (n = 121) | crude | adjusted | |||||||||
n | % | n | % | OR (95%CI) | p | OR (95%CI)a | P | n | % | n | % | OR (95%CI) | p | OR (95%CI)a | p | |
OGG1 | ||||||||||||||||
Ser/Ser | 10 | 25.0 | 39 | 32.2 | 1.00 | 1.00 | 5 | 21.7 | 39 | 32.2 | 1.00 | 1.00 | ||||
Ser/Cys,Cys/Cys | 30 | 75.0 | 82 | 67.8 | 1.43 (0.63–3.21) | 0.390 | 1.28 (0.55–2.99) | 0.567 | 18 | 78.3 | 82 | 67.8 | 1.71 (0.59–4.95) | 0.321 | 1.66 (0.56–4.87) | 0.359 |
MUTYH | ||||||||||||||||
Gln/Gln | 4 | 10.0 | 37 | 30.6 | 1.00 | 1.00 | 3 | 13.0 | 37 | 30.6 | 1.00 | 1.00 | ||||
Gln/His,His/His | 36 | 90.0 | 84 | 69.4 | 3.96 (1.32–11.95) | 0.014 | 3.95 (1.28–12.20) | 0.017 | 20 | 87.0 | 84 | 69.4 | 2.94 (0.82–10.49) | 0.097 | 3.06 (0.84–11.11) | 0.089 |
APEX1 | ||||||||||||||||
Asp/Asp | 12 | 30.0 | 70 | 57.9 | 1.00 | 1.00 | 11 | 47.8 | 70 | 579 | 1.00 | 1.00 | ||||
Asp/Glu,Glu/Glu | 28 | 70.0 | 51 | 42.1 | 3.20 (1.49–6.89) | 0.003 | 3.04 (1.38–6.71) | 0.006 | 12 | 52.2 | 51 | 42.1 | 1.50 (0.61–3.66) | 0.376 | 1.61 (0.64–4.09) | 0.315 |
XRCC1 | ||||||||||||||||
Arg/Arg | 25 | 62.5 | 62 | 51.2 | 1.00 | 1.00 | 14 | 60.9 | 62 | 51.2 | 1.00 | 1.00 | ||||
Arg/Gln,Gln/Gln | 15 | 37.5 | 59 | 48.8 | 0.63 (0.30–1.31) | 0.217 | 0.60 (0.28–1.30) | 0194 | 9 | 39.1 | 59 | 48.8 | 0.68 (0.27–1.68) | 0.398 | 0.62 (0.24–1.58) | 0.315 |